Identity
Arabinose is a pentose proposed as a selective prebiotic substrate for supporting neisseria mucosa and gemella sanguinis in cystic-fibrosis airway microbiome formulations. 1
- Canonical name: Arabinose. 1
- Known aliases: None reported in the source document. 1
- Stable external identifier: None reported in the source document. 1
- Entity type: Compound. 1
Evidence from cf_formulation_design
The report identified arabinose as one of six pathways complete in at least one core commensal species but absent or nearly absent in PA14. 1
PA14 pathway completeness for arabinose was 0%, and the corresponding selectivity value was 1.00. 1
The proposed formulation strategy predicts that arabinose could support neisseria mucosa and gemella sanguinis while limiting direct nutritional support for PA14. 1
This arabinose-based prebiotic prediction requires experimental validation before use. 1
Comparative evidence from pseudomonas_carbon_ecology
A comparative analysis of 7 pseudomonas-aeruginosa-group species and 189 pseudomonas e species found arabinose completeness of 0.0% versus 62.6%, respectively; this difference was among 43 of 62 pathways significant after Benjamini-Hochberg false-discovery-rate correction at q < 0.05. 2
This broader comparison supports the existing observation that arabinose availability can distinguish the PA14-associated host-pathogen context from candidate commensals, while refining it by showing that arabinose loss is also characteristic of the wider Pseudomonas s.s. group relative to Pseudomonas_E, rather than evidence specific to PA14 alone. 2
The comparative result is consistent with pathway loss in host-associated clades, but it does not directly test the proposed cystic-fibrosis formulation or establish selective growth of either commensal. 2
Relations
Arabinose contributes to the metabolic-gap analysis in metabolic-model-gapfilling, where pathway completeness differences between PA14 and candidate commensals identify selective substrate targets. 1
Its proposed use also relates to condition-specific competitive fitness in condition-specific-fitness and the integrated formulation workflow described in Rational Design of Protective Microbiome Formulations for Competitive Exclusion of *Pseudomonas aeruginosa* in Cystic Fibrosis Airways. 1
The comparative pathway-loss result supports the gene-content and ecological-niche framing in ecotype-environment-gene-content and refines interpretation of arabinose as a clade-level metabolic marker; further context is provided by Carbon Source Utilization Predicts Ecology and Lifestyle in Pseudomonas. 2